NeOnc Technologies Appoints New Chief Accounting Officer

An update from NeOnc Technologies Holdings, Inc. ( (NTHI) ) is now available.

On March 12, 2026, NeOnc Technologies Holdings, Inc. appointed David Choi as Chief Accounting Officer and entered into an employment agreement granting him a $162,500 annual base salary and 170,000 restricted shares, with time-based and performance-based vesting. The appointment, announced publicly on March 13, 2026, reflects NeOnc’s effort to reinforce financial reporting, internal controls, and governance as it advances its clinical-stage CNS cancer platform and grows as a public company.

Choi, 32, brings more than a decade of experience in technical accounting, SEC reporting, and internal controls from roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young, and he is a Certified Public Accountant with advanced degrees from the University of California, Irvine. His mandate to build scalable finance infrastructure and support Sarbanes-Oxley compliance underscores NeOnc’s focus on strengthening its finance function to support accelerating clinical trials, global expansion, and long-term value creation for shareholders.

The most recent analyst rating on (NTHI) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock, see the NTHI Stock Forecast page.

Spark’s Take on NTHI Stock

According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral.

The score is held back primarily by weak financial fundamentals (large losses, negative equity, and heavier cash burn), partially offset by constructive technicals with the stock trading above key moving averages and moderate momentum. Valuation is also a drag due to the negative P/E and lack of dividend yield.

To see Spark’s full report on NTHI stock, click here.

More about NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing central nervous system therapeutics that address the challenges of the blood-brain barrier. Its NEO drug development platform has produced proprietary chemotherapy agents, including NEO100 and NEO212, which are in Phase II human clinical trials under FDA Fast-Track and IND status and are backed by an extensive patent portfolio licensed from the University of Southern California.

The company targets aggressive brain cancers and other oncological and neurological conditions with novel therapies and delivery methods protected by patents extending to 2038. Its platform-based approach and licensing strategy position NeOnc in the CNS oncology space, where it aims to convert promising laboratory and early clinical results into commercially viable treatments as it scales its global operations.

Average Trading Volume: 58,035

Technical Sentiment Signal: Hold

Current Market Cap: $203.5M

For detailed information about NTHI stock, go to TipRanks’ Stock Analysis page.